Zachary C. Howard

Array ( [id] => 20108292 [patent_doc_number] => 12359000 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Anti-8-hydroxy-2'-deoxyguanosine antibody or antibody fragment thereof, production method, kit, measuring method, and device for measurement [patent_app_type] => utility [patent_app_number] => 17/626755 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 15 [patent_no_of_words] => 19345 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1180 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17626755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990197 [patent_doc_number] => 20220356234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => COMPLEMENT INHIBITORS FOR TREATING DRUG-INDUCED COMPLEMENT-MEDIATED RESPONSE [patent_app_type] => utility [patent_app_number] => 17/764781 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17764781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17982609 [patent_doc_number] => 20220348645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => CONFORMATION-SPECIFIC ANTIBODIES THAT BIND NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELLS [patent_app_type] => utility [patent_app_number] => 17/765514 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -146 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17765514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020636 [patent_doc_number] => 20220372135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => METHODS FOR TREATING MYELOFIBROSIS AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/764142 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44210 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -90 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17764142 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16727890 [patent_doc_number] => 20210095037 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => METHODS FOR TREATING LATE-ONSET ASTHMA USING BENRALIZUMAB [patent_app_type] => utility [patent_app_number] => 17/031965 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17031965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990203 [patent_doc_number] => 20220356240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => ANTI-INFLAMMATORY THERAPY IN ARRHYTHMOGENIC CARDIOMYOPATHY (ACM) [patent_app_type] => utility [patent_app_number] => 17/763780 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990203 [patent_doc_number] => 20220356240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => ANTI-INFLAMMATORY THERAPY IN ARRHYTHMOGENIC CARDIOMYOPATHY (ACM) [patent_app_type] => utility [patent_app_number] => 17/763780 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960070 [patent_doc_number] => 20220340650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => COMBINATION THERAPY WITH CGRP ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/763925 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18020637 [patent_doc_number] => 20220372136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => METHODS FOR TREATING ANEMIA OF CHRONIC DISEASE [patent_app_type] => utility [patent_app_number] => 17/764143 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43785 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -91 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17764143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18242125 [patent_doc_number] => 20230074436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/761088 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16539452 [patent_doc_number] => 20200405865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL [patent_app_type] => utility [patent_app_number] => 17/019722 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9328 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019722 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18147404 [patent_doc_number] => 20230021261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => THERAPEUTIC COMPOSITION AND ADMINISTRATION METHODS FOR INCREASING OSSEOINTEGRATION WITH DENTAL IMPLANTS, GRAFT MATERIALS AND PRF [patent_app_type] => utility [patent_app_number] => 17/757353 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17757353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18019079 [patent_doc_number] => 20220370578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => IMMUNOGENIC PEPTIDE FRAGMENTS OF METALLOPROTEASE ADAMTS-7 AND USES THEREOF IN ANTI-ATHEROSCLEROSIS AND RELATED DISEASES [patent_app_type] => utility [patent_app_number] => 17/642837 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17642837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955185 [patent_doc_number] => 20240043512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => EPITOPES OF ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/641780 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18153106 [patent_doc_number] => 11566067 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-31 [patent_title] => Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof [patent_app_type] => utility [patent_app_number] => 16/996623 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 28839 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955185 [patent_doc_number] => 20240043512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => EPITOPES OF ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/641780 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955185 [patent_doc_number] => 20240043512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => EPITOPES OF ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/641780 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29055 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20438679 [patent_doc_number] => 12509506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-30 [patent_title] => Anti-Hog TCN1 monoclonal antibodies and methods of production and use thereof [patent_app_type] => utility [patent_app_number] => 17/633131 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 14491 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 535 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17633131 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16582867 [patent_doc_number] => 20210017269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/988257 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961638 [patent_doc_number] => 12331122 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Anti-ASGR-1 monoclonal inhibitory antibodies [patent_app_type] => utility [patent_app_number] => 16/987237 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4127 [patent_figures_cnt] => 61 [patent_no_of_words] => 130507 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987237 [rel_patent_id] =>[rel_patent_doc_number] =>)